How many clinical trials are tracked of setmelanotide?

12 trials are tracked, 5 with published results.

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Dermatology Urology Emergency Medicine Ophthalmology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

setmelanotide

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of setmelanotide

12 trials tracked of setmelanotide: 6 in phase 3 or 4 and 5 with published results. The most-cited published study has 456 citations.

12Trials tracked

6Phase 3 & 4

0Recruiting

5With published results

Phase distribution

Phase 4 1 Phase 3 5 Phase 2 6

Phase 3 Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity Completed · 456 cited
Phase 3 Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity Completed · 456 cited
Phase 3 Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity Completed · 178 cited
Phase 3 Long Term Extension Trial of Setmelanotide Completed · 56 cited
Phase 3 Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity Completed · 36 cited
Phase 4 Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants Completed

Show 6 more trials

Phase 2 Open-Label Study of Setmelanotide in Hypothalamic Obesity Completed
Phase 2 Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity Completed
Phase 2 Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients Completed
Phase 2 Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome Completed
Phase 2 DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway Completed
Phase 2 Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants Completed

Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.